Ozagrel hydrochloride hydrate
SIGMA/O1385 - ≥98% (HPLC), solid
Synonym: (E)
CAS Number: 78712-43-3
Empirical Formula (Hill Notation): C13H12N2O2 · HCl · xH2O
Molecular Weight: 264.71 (anhydrous basis)
MDL Number: MFCD00911569
Linear Formula: C13H12N2O2 · HCl · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | solid |
| InChI | 1S/C13H12N2O2.ClH.H2O/c16 |
| InChI key | OWIZTYOMGVTSDP-TXOOBNKBSA |
| Quality Level | 100 ![]() |
| SMILES string | O.Cl.OC(=O)C=Cc1ccc(Cn2 |
| solubility | H2O: soluble |
| storage condition | desiccated |
| storage temp. | room temp |
| Application: | Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor: • in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction • to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes • to test its effect on arteriolar vasoconstriction in hyperglycemic mice |
| Biochem/physiol Actions: | Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor. |
| Biochem/physiol Actions: | Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |

